Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced or Metastatic EGFR Mutated NSCLC.”

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT04063462
What this trial is testing

Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation

Who this might be right for
Non Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital 60
Large-scale testing (Phase 3)Study completedNCT02454933
What this trial is testing

Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours

Who this might be right for
Locally Advanced or Metastatic EGFR T790M+ NSCLC
AstraZeneca 29
Large-scale testing (Phase 3)Active Not RecruitingNCT04143607
What this trial is testing

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

Who this might be right for
Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd. 337
Testing effectiveness (Phase 2)Study completedNCT01250119
What this trial is testing

Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 688
Post-approval studies (Phase 4)Study completedNCT01203917
What this trial is testing

Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Who this might be right for
Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
AstraZeneca 1,060
Large-scale testing (Phase 3)Looking for participantsNCT06674343
What this trial is testing

Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations

Who this might be right for
Advanced or Metastatic Non-small Cell Lung Cancer
Peking Union Medical College Hospital 144
Testing effectiveness (Phase 2)Active Not RecruitingNCT04036682
What this trial is testing

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerEGFR Exon 20 Mutation
Cullinan Therapeutics Inc. 284
Testing effectiveness (Phase 2)Active Not RecruitingNCT06827145
What this trial is testing

Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC

Who this might be right for
Non-Small-Cell Lung Cancer
National Cancer Center, China 30
Testing effectiveness (Phase 2)Ended earlyNCT03318939
What this trial is testing

Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

Who this might be right for
NSCLC
Spectrum Pharmaceuticals, Inc 648
Large-scale testing (Phase 3)Looking for participantsNCT06350097
What this trial is testing

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 582
Testing effectiveness (Phase 2)Active Not RecruitingNCT06120140
What this trial is testing

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 305
Large-scale testing (Phase 3)Study completedNCT01774721
What this trial is testing

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Who this might be right for
Non-small Cell Lung Cancer With EGFR-Activating Mutations
Pfizer 452
Testing effectiveness (Phase 2)Looking for participantsNCT06962865
What this trial is testing

A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
RemeGen Co., Ltd. 80
Testing effectiveness (Phase 2)Study completedNCT02108964
What this trial is testing

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Who this might be right for
Advanced Non-small Cell Lung Cancer
Novartis Pharmaceuticals 225
Testing effectiveness (Phase 2)Looking for participantsNCT06668103
What this trial is testing

Clinical Study of Combination Therapy With ABSK043 and Firmonertinib

Who this might be right for
Non-Small Cell Lung Cancer With EGFR Mutation
Abbisko Therapeutics Co, Ltd 54
Large-scale testing (Phase 3)Study completedNCT04206072
What this trial is testing

D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC

Who this might be right for
Non-Small Cell Lung CancerEGFR Gene Mutation
Betta Pharmaceuticals Co., Ltd. 362
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06672068
What this trial is testing

TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC

Who this might be right for
NSCLC
TYK Medicines, Inc 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06182761
What this trial is testing

Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
NSCLC
Shanghai Zhongshan Hospital 45
Not applicableApproved For MarketingNCT01649284
What this trial is testing

Afatinib Expanded Access Program

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim
Testing effectiveness (Phase 2)UnknownNCT05519293
What this trial is testing

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

Who this might be right for
Non-small Cell Lung Cancer
RedCloud Bio 76
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation